Carboxyamidotriazole

In response to the clinical pain points of strong toxic and side effects and high tendency to develop drug resistance of traditional chemotherapeutic drugs in the treatment of solid tumors, carboxyamidotriazole, as a new imidazole anti-tumor drug candidate, has demonstrated unique clinical value. Its mechanism of action is different from that of conventional cytotoxic drugs. It can inhibit the activity of mitochondrial respiratory chain complex I, down-regulate the expression of hypoxia-inducible factor-1α, and simultaneously block the proliferation signaling pathway of tumor cells and the process of neovascularization. At present, it has shown definite anti-tumor activity against non-small cell lung cancer, melanoma, renal cancer and other types of solid tumors in clinical studies, and has potential application potential especially for patients with advanced solid tumors that are resistant to conventional treatments.

Currently, carboxyamidotriazole is still in the global clinical trial stage and has not been commercially launched yet, and there is no publicly available market size statistical data worldwide. As this drug is a First-in-class candidate, the current R&D pipeline is mainly led by the original research institution, and no generic drug enterprises have laid out related pipelines, so the market competition pattern is highly concentrated. If it successfully completes the Phase III clinical trial and is approved for marketing in the future, it is expected to fill the clinical gap in the second-line treatment of some solid tumors, and the market growth space will depend on the scope of approved indications and medical insurance coverage.

Carboxyamidotriazole was originally developed by the Institute of Materia Medica, Chinese Academy of Medical Sciences. It has not been approved for marketing yet and has no corresponding trade name. The core patent of this compound expired in 2020, and the related preparation patent is expected to expire in 2032. The currently under-research dosage form is mainly oral tablets, with the mainstream specification of 100 mg per tablet, and it has not been included in the Chinese Catalogue of Chemical Drugs or the FDA Reference Listed Drug Directory. Up to now, there is no carboxyamidotriazole API that has obtained the CDE registration number in China, and no related preparation products have been approved for marketing. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for carboxyamidotriazole. All products meet the requirements of Chinese Pharmacopoeia and relevant FDA regulations. Most products are in regular stock. Spot orders submitted before 16:00 can be shipped on the same day, which can fully meet the needs of various scenarios such as impurity research and quality control in the drug R&D stage.